Table 1.
Surface markers in USCs | % of expression | References | |
---|---|---|---|
Embryonic stem cell markers | TRA-1–81 | ± | [42] |
TRA-1–60 | ± | [42] | |
SSEA4 | + | [42] | |
Epithelial markers | E-cadherin | + | [32, 52] |
β-catenin | + | [32, 52] | |
Occludin | + | [32] | |
Claudin 1 | + | [32] | |
ZO-1 | + | [32, 52] | |
KRT7 | + | [8, 32, 52] | |
KRT14 | + | [53] | |
KRT15 | + | [53] | |
KRT16 | + | [53] | |
KRT18 | + (type I),—(type II) | [41] | |
KRT19 | + | [53] | |
CD326 | + | [53] | |
Epithelial basal markers | CD44 | + | [25, 38, 54] |
Renal epithelial markers | CD13 | + | [23, 32, 44, 52] |
L1CAM | + | [52] | |
NR3C2 | + | ||
SLC2A1 | + | ||
CD24 | + | [41] | |
CD29 | + | ||
CD34 | − | ||
CD73 | + | ||
CD90 | + | ||
CD105 | + | ||
CD133 | ± | ||
UMOD | + (type I),—(type II) | ||
NPHS1 | + (type I),—(type II) | ||
AQP1 | + (type I),—(type II) | ||
AQP2 | − | ||
SLC12A1 | + (type I),—(type II) | ||
Mesenchymal stem cells markers | SSEA-4 | + | [25, 55] |
CD29 | + | [38, 44] | |
CD73 | + | [25, 31, 38, 55] | |
CD90 | + | [31, 38, 44] | |
CD105 | ± | [25, 31, 38, 44] | |
CD166 | + | [44] | |
STRO-1 | + | [25] | |
Fibroblast markers | Actin | + | [32, 52] |
Vimentin | ± | [32, 52] | |
Fibronectin | ± | [32, 52] | |
Twist 1 | − | [32] | |
Slug | − | [32] | |
Pericyte markers | CD146 | ± , + | [25, 31, 42] |
NG2 | ± | [25, 42] | |
PDGF-rβ (CD 140b) |
± | [25, 42] | |
Hematopoietic stem cells markers | CD11b | − | [42, 56] |
CD14 | − | [56] | |
CD31 | − | [25] | |
CD34 | − | [25, 31, 38, 44] | |
CD45 | -, ± | [25, 31, 44, 54] | |
CD133 | ± | [25, 38] | |
CD309 | − | [38] | |
HLA-ABC (MHC-1) | + | [42, 57] | |
HLA-DR (MHC-II) | − | [38, 42, 44, 51] |
−: percentage of expression < 1%, ± : 1% < percentage of expression < 50%, + : percentage of expression > 50%